All results
5 results for randomized multicenter open label phase iii study evaluate efficacy and safety
-
ALXN2050-NEPH-201
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Avidity FSHD
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory…
- Ages
- 18 Years - 65 Years
- Sexes
- All
-
BOSTON 3
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and…
- Ages
- 18 Years - N/A
- Sexes
- All
-
EN20-01
The primary objective of this study is to evaluate the safety and efficacy of CNTX-6970 for the treatment of pain related to OA of the knee compared to…
- Ages
- 40 Years - 90 Years
- Sexes
- All
-
Study of XL092 in Comb. with Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor…
- Ages
- 18 Years - N/A
- Sexes
- All